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A B S T R A C T
Background: The role of new antiepileptic drugs (AED) in the treatment of status epilepticus (SE) is of
interest, especially in benzodiazepine-resistant status epilepticus where phenytoin is deemed
inappropriate due to allergy or comorbidity. Levetiracetam (LEV) is a new AED with few side effects.
It is easy to administer. Reports exist of its use in SE in adults.
Aims: To clarify the evidence for use of LEV as an alternative stage two AED in treatment of SE by a
systematic review of the literature.
Method: An online MEDLINE search identiﬁed 118 articles. The abstracts were screened for studies
written in English, in which (1) at least two adults had been treated, and (2) LEV had been administered
intravenously as the ﬁrst AED, on its own or together with benzodiazepines. Ten studies were included.
Results: Out of the ten studies, seven were retrospective observational, two prospective observational,
and one prospective randomized. The studies described a total of 334 patients. The most common reason
for administrating LEV was that standard treatment was deemed inappropriate. The efﬁcacy ranged from
44% to 94%, with higher efﬁcacy reported in the retrospective studies.
Conclusions: The evidence for use of LEV as an alternative stage two AED in SE is limited. The higher
efﬁcacy reported in retrospective studies indicates possible publication bias, and caution is advised when
the results of these retrospective studies are considered in clinical decision-making.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The standard treatment for status epilepticus (SE) in Europe is
benzodiazepines in treatment stage one, which is followed by
phenytoin or its equivalents in treatment stage two, and in
refractory cases sedation and intensive care in treatment stage
three.1,2 This treatment regime carries risks, especially for certain
patient categories. For instance, phenytoin is associated with
circulatory side effects, which makes the drug unsuitable for frail,
elderly, or cardiologically compromised patients. Other antiepi-
leptic drugs (AED) such as valproic acid, levetiracetam (LEV), and
lacosamide have therefore attracted interest as alternative stage
two AEDs in cases where phenytoin is not appropriate due to
allergy or comorbidities.1
LEV is one of the newer AEDs. Introduced in 1999, the drug has
achieved rapid spread in clinical practice, due in large part to its
pharmacological properties (e.g. minimal protein-binding and
drug–drug interactions).3 Compared to many other AEDs, LEV
has fewer reported major side effects, although this may be a
consequence of its relatively short period of clinical use. Some* Corresponding author. Tel.: +46 707730675.
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doi:10.1016/j.seizure.2012.01.008years ago, reports on the use of LEV as an add-on therapy in
treatment of SE emerged.4,5 Theoretically, the excellent safety
proﬁle of LEV and its broad spectrum efﬁcacy make it a good
candidate for use in frail patients with SE. Following the
introduction of an intravenous preparation in 2006, some
literature has accumulated on this topic.
The initial case series on the use of LEV in SE reported the drug
to be highly successful in terminating seizures.4,6–8 Subsequent
studies and reviews have somewhat modulated this view, but
despite this LEV is still considered one of the possible AEDs for use
in the treatment of SE. However, many of the above studies
describe the use of LEV as an add-on treatment in SE in addition to
other AEDs, and have therefore failed to clarify the beneﬁts of LEV
as an alternative stage two AED in patients where standard
treatment cannot be given.4,6 We are interested in the clinical
problem of patients with benzodiazepine-resistant SE where
phenytoin is deemed inappropriate. The clinician is then faced
with the dilemma of either administrating an alternative AEDs or
proceeding directly to intensive care, which also carries risks.
Against this background, we wanted to clarify the evidence for
the use of LEV as an alternative stage two AED in SE and undertook
a systematic review of the literature. Because of the scarcity of
randomized evidence regarding treatment of SE, we did not expect
to ﬁnd studies ﬁt for a meta-analysis. Instead, the aim of the studyvier Ltd. All rights reserved.
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on studied patient populations, efﬁcacy and safety.
2. Methods
We ﬁrst searched the literature for studies describing the use of
LEV as a ﬁrst-line AED. The inclusion criteria were any study
written in the English language describing more than two adult
patients with: (1) SE, and; (2) LEV administered intravenously as
the ﬁrst AED, either on its own or together with or after
benzodiazepines. The sought outcome measures were efﬁcacy in
terminating SE and reported adverse effects. For adverse events,
we used a conservative approach and included all events reported
for patients initially treated with LEV, regardless of subsequent
administration of other AEDs. We also compiled information about
the study populations.
An online MEDLINE search in January 2011 for ‘‘Levetiracetam
status epilepticus’’ resulted in 118 articles. The abstracts were
assessed and 17 studies selected for additional analysis. Nine
studies met the inclusion criteria. One study was excluded because
the outcome of the relevant patients could not be extracted from
the reported data, leaving eight studies.5,7–13 To make sure that our
search had adequately covered the literature, articles cited in the
selected studies were also examined. This reference screening did
not reveal any studies that had not been identiﬁed in the initial
search. During the review process, two more relevant studies were
published and added to the manuscript.14,15 Some methodological
differences between the reviewed studies had to be reconciled for a
digestible presentation. For instance, some of the larger studies
describe the use of LEV in episodes of SE and the same patients may
have been included multiple times.
3. Results
Of the ten studies included, all but one15 were performed in
Europe. In these studies, which described a total of 334 patientsTable 1
Studies included in this review and description of study populations.
Study Country Sample (described patients receiving iv LEV  
Retrospective
Aiguabella 2011 Spain 13 out of 40 patients treated during 2008 in 8
where standard treatment with phenytoin or 
was contraindicated. All patients suffered foca
Alvarez 2011 Switzerland 58 patients retrospectively identiﬁed in a pros
kept registry of SE patients 2006–2011.
Fatouch 2010 Italy 9 patients over 65 years of age where standar
was considered unsafe. 8 patients suffered pa
1 generalized SE.
Berning 2009 Germany 27 out of 32 patients treated at 2 hospitals be
May 2007 and February 2008 where standard
was deemed unsafe.
Ga´mez-Leyva 2009 Spain 16 out of 34 patients treated with iv LEV July
8 patients suffered focal and 8 suffered gener
Beyenburg 2008 Luxembourg 5 out of 14 patients treated with iv LEV for SE
complex partial seizures during 2007.
Knake 2008 Germany 13 out of 16 patients treated with iv LEV for S
May 2006 and February 2007. All suffered foc
Prospective
Uges 2009 Netherlands 9 out of 11 patients in a safety trial received i
ﬁrst non-BZ AED for SE. Four suffered focal an
generalized SE.
Eue 2009 Germany 43 hospitalized patients where SE was not co
bensodiazepines and who did not tolerate phe
phenobarbital. 35 suffered focal and 8 suffere
Misra 2011 India 48 out of 79 patients received iv LEV on its ow
failure of lorazepam.treated with LEV, 55 patients had received LEV alone and 279 had
received LEV in conjunction with benzodiazepines. Because of the
large variability in the size of the studies, their different treatment
protocols, and their observational nature, a quantitative meta-
analysis of the data was considered inappropriate. Instead, we
focused on qualitatively describing the literature.
All reviewed studies but one were observational and uncon-
trolled. Seven studies were retrospective and three studies were
prospective, out of which one was randomized.15 In most studies,
where that information was presented, there was a majority of
focal SE among the patients receiving LEV as an alternative AED.
The deﬁnition of SE varied somewhat between the studies. Some
authors used a time limit of 30 min with seizure or clusters of
seizures without intervening restoration of consciousness. Other
authors used the more aggressive time limit of ﬁve minutes.
Importantly, in a majority of the studies it was clearly stated that
patients received iv LEV because standard treatment was deemed
inappropriate. Doses given in the reviewed studies varied from 250
to 2500 mg. For efﬁcacy, we relied on the deﬁnitions used by the
authors. This was generally a cessation of clinical seizure activity or
seizure activity on EEG within a certain time frame without the
need for any additional antiepileptic drugs. The efﬁcacy measure-
ment for each study is shown in Table 1. The reported efﬁcacy
(Table 2) was 44% in two prospective studies, and 75% in one
prospective study. Efﬁcacy ranged from 60% to 94% in the
retrospective studies.
With regards to safety, none of the studies reported any serious
side effects related to treatment with LEV. Sedation was the most
common side effect, occurring in quantities ranging from 12.5% to
40%. All side effects are listed in Table 2.
4. Discussion
Here we have reviewed the published experience of LEV as an
alternative stage two AED in the treatment of SE. SE is a clinical
scenario well known for its lack of randomized controlledBZ) Deﬁnition of treatment effect
 hospitals,
valproate
l SE.
Clinical or EEG cessation of seizures within 24 h after
start of iv LEV without need for other AED
pectively Need to introduce a further compound to control SE.
d treatment
rtial and
Disappearance or signiﬁcant reduction of EEG
abnormalities and subsequent clinical improvement.
tween
 treatment
Cessation of SE as shown by neurologic examination,
electroencephalography (EEG), or both
 2007–July2008.
alized SE.
(i) The absence of seizures within, at most 24 h after
iv levetiracetam was infused; (ii) no other antiepileptic
drugs administered during this time; and (iii) no
recurrence of status epilepticus during the hospital stay
 or series of Complete seizure cessation in the 24 h after starting LEV IV
E between
al SE.
Not stated
v LEV as the
d ﬁve suffered
Not stated
ntrolled by
nytoin or
d generalized SE.
Cessation of the clinical manifestation of convulsive
SE and lectroencephalographically in non-convulsive
and subtle SE within approximately 3 min.
n or after Primary endpoint was clinical seizure cessation within
30 min and secondary endpoints were 24-h seizure
freedom, mortality, and adverse events.
Table 2
Efﬁcacy, dose, and side effects in the reviewed studies.
Study Patients receiving
BZ + LEV/only LEV
Efﬁcacy Dose LEV Side effects
Retrospective
Aiguabella 2011 8/5 77% 1000–1500 mg 15% somnolence 1 trombocytopenia
Alvarez 2011 58/0 52% 20 mg/kg Not stated
Fatouch 2010 0/9 89% 1500 mg Not stated
Berning 2009 25/2 74% 1000–3000 mg Sedation (6/32), nausea (1/32), liver enzymes (1/32)
Ga´mez-Leyva 2009 16/0 94% 500–1500 mg None
Beyenburg 2008 4/1 80% 250–1000 mg Sedation 4/10
Knake 2008 13/0 85% 250–1500 mg Sedation 2/16
Prospective
Uges 2009 9/0 44% 2500 mg Respiratory 2/9, red face 1/9
Eue 2009 43/0 44% 1000 or 2000 mg Somnolnce ‘‘common’’
Misra 2011 10/38 75% 20 mg/kg Agitation 4, rash 1, thrombocytopenia 4,
pneumonia 8, urinary infection 1
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traditionally categorized as low-grade evidence – with one notable
exception, Misra et al., which is discussed in detail below.
Regarding study design, all studies except Misra et al. were
observational and uncontrolled. The majority were retrospective
and small. The main method used to ﬁnd patients was retrospec-
tive analysis of the medical records for all patients treated with iv
LEV during a deﬁned period. In the reviewed studies, the reported
efﬁcacy for patients treated with LEV as a ﬁrst line AED ranged
from 44% to 94%. We believe that the most interesting ﬁnding in
our review is that higher efﬁcacy was reported in the retrospective
studies compared to the prospective ones (Fig. 1). This indicates a
possible publication or selection bias in some of the retrospective
data. For example, centers with a less favorable experience with
LEV in SE might have refrained from further use of the drug and
thereby publication. Another possible explanation for the large
variability in efﬁcacy is variation in the study populations and the
small number of patients in some of the studies.
The differences between the prospective studies underline the
need for further investigation into the use of LEV in SE. The
differences between the two large prospective studies in this
review, which report efﬁcacies of 44% and 75% respectively, are
most likely due to differences in patient population and treatment
protocol.11,15 In Eue et al., an observational study where the
efﬁcacy was 44%, many patients were elderly, their SE was not
controlled by bensodiazepines, and they were judged not to
tolerate phenytoin or phenobarbital. In Misra et al., a randomizedFig. 1. Box plot comparing the reported efﬁcacy in the retrospective versus the
prospective studies. Box indicates median and ﬁrst and third interquartile range,
error bars represent max and min.study where efﬁcacy was 75%, LEV was administered as ﬁrst
treatment without prior bensodiazepines. The patient population
in Misra et al. was younger and it is likely that many of those
responding to LEV as ﬁrst-line treatment would have also
responded to benzodiazepines. However, the absence of benzodi-
azepine treatment is most likely not the explanation for the large
difference in efﬁcacy compared to Eue et al., since even among
patients refractory to Lorazepam, Misra et al. report efﬁcacy of LEV
in seven out of ten patients. While this patient group is very small
in Misra et al., it still indicates that differences in study
populations, for example etiology and demographics, underpin
some of the dissimilarities between Eue et al. and Misra et al.
It is important to note that the patient populations described in
the reviewed articles are most likely not representative of patients
with SE in general. In at least six of the studies it is clearly stated
that the reason for giving iv LEV was because standard treatment
was considered inappropriate, for instance due to circulatory
instability or known drug allergy. This is well in line with the
clinical scenario we set out to investigate, but more importantly
means that the patient population might be frailer or have more
co-morbidities than patients with SE who are able to receive the
standard treatment. One should therefore avoid drawing conclu-
sions from these studies regarding the efﬁcacy of LEV for SE in
patients where standard treatment is not contraindicated, and the
efﬁcacy of LEV reported therein should not be compared with that
of, for instance, phenytoin in regular patients with SE. Another
important point regarding the current literature is that many of the
studies were not designed to prove efﬁcacy, but merely to publish
the clinical experience with LEV. This might explain the very small
number of patients in some of the case series. Finally, in many of
the reviewed studies the majority of patients suffered focal
seizures, which makes it even harder to draw conclusions
regarding the efﬁcacy of LEV in all patients with SE. In fact, some
authors report failure of LEV in generalized SE, but good effects in
non-convulsive SE.11 Whether LEV might be of more value in
treatment of focal rather than in generalized SE is a very important
issue to address in future studies.
With regard to safety, the data in the reported studies conﬁrms
the previous picture of LEV as a relatively safe drug, although
thrombocytopenia was noted in some patients. This side effect has
attracted increasing attention in recent years and should be closely
monitored in future trials.16 The most commonly reported side
effect was sedation/somnolence, which is common in all treatment
regimes of SE. It is important to bear in mind that in our
compilation we decided to include all side effects stated for
patients initially treated with LEV with or without benzodiaze-
pines, even if those patients later received other AEDs. This
conservative approach, chosen so as not to underestimate the
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cases of sedation were not attributed to LEV, but to benzodiaze-
pines or other AEDs. Nonetheless, the reviewed studies support the
notion that LEV is a relatively safe AED, although long-term side
effects may have not emerged yet. The relatively good safety
proﬁle of the drug is underlined by the fact that the majority of the
studies were performed on patients where co-morbidity prevented
the use of standard treatment.
We conclude that the evidence for LEV as an alternative stage
two AED in SE is scarce. The number of patients described in the
literature is still low and the data is largely uncontrolled and
observational. The patient populations in the reviewed studies are
very heterogeneous, not only regarding personal characteristics
such as age, but also the etiology of the SE and the reason for
selecting iv LEV as the treatment.
Pending randomized controlled data comparing the efﬁcacy of
LEV to that of phenytoin, valproic acid, and other potential ﬁrst-
line AEDs, the main use of LEV will most likely remain cases of
SE where standard treatment is contraindicated. Given the mild
side effects associated with LEV described in the reviewed
studies, we think that this use might be motivated in selected
cases, as suggested by the most current consensus document.1
However, clinicians should be aware of the current paucity of
evidence and be cautious in order that administration of LEV does
not unduly delay progression to the next treatment stage. As
indicated in one of the most recent studies, LEV might not be the
ﬁrst alternative AED to consider if phenytoin is contraindicated,
since LEV might be less effective than both phenytoin and
valproate in terminating SE.14 It should also be noted that LEV is
not licensed for use in status epilepticus, so the medico-legal
situation of each speciﬁc country determines whether it is an
available treatment option.
In current high-quality reviews, LEV is listed as an alternative
stage two AED in the treatment of SE.1,17 Our short review supports
this notion, but also demonstrates that different centers have
varying experiences with LEV, underlining the need for more
randomized data before the place of LEV in treatment of SE can
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